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A B S T R A C T   
Background: There is a lack of precision medicine in pancreatic ductal adenocarcinoma (PDA) and related cancers, and outcomes for patients with this diagnosis 
remain poor despite decades of research investigating this disease. Therefore, it is necessary to explore novel therapeutic options for these patients who may benefit 
from personalized therapies. 
Objective: Molecular profiling of hepatopancreaticobiliary malignancies at our institution, including but not limited to PDA, was initiated to assess the feasibility of 
incorporating molecular profiling results into patient oncological therapy planning. 
Methods: All eligible patients from Thomas Jefferson University (TJU) with hepatopancreaticobiliary tumors including PDA, who agreed to molecular testing 
profiling, were prospectively enrolled in a registry study from December 2014 to September 2017 and their tumor samples were tested to identify molecular markers 
that can be used to guide therapy options in the future. Next generation sequencing (NGS) and protein expression in tumor samples were tested at CLIA-certified 
laboratories. Prospective clinicopathologic data were extracted from medical records and compiled in a de-identified fashion. 
Results: Seventy eight (78) patients were enrolled in the study, which included 65/78 patients with PDA (local and metastatic) and out of that subset, 52/65 patients 
had surgically resected PDA. Therapy recommendations were generated based on molecular and clinicopathologic data for all enrolled patients. NGS uncovered 
actionable alterations in 25/52 surgically resected PDAs (48%) which could be used to guide therapy options in the future. High expression of three proteins, TS (p ¼
0.005), ERCC1 (p ¼ 0.001), and PD-1 (p ¼ 0.04), was associated with reduced recurrence-free survival (RFS), while TP53 mutations were correlated with longer RFS 
(p ¼ 0.01). 
Conclusions: The goal of this study was to implement a stepwise strategy to identify and profile resected PDAs at our institution. Consistent with previous studies, 
approximately half of patients with resected PDA harbor actionable mutations with possible targeted therapeutic implications. Ongoing studies will determine the 
clinical value of identifying these mutations in patients with resected PDA.   
1. Introduction 
In recent years, there has been great interest in the role that precision 
medicine might play in the treatment of patients with pancreatic ductal 
adenocarcinoma (PDA) who have an overall five year survival rate of 
nine percent [1]. After decades of research investigating this devastating 
disease, the main treatment options for advanced disease are a 
combination of chemotherapeutics [2,3] that offer only a limited sur-
vival benefit [4,5]. For example, ESPAC-4 showed a survival benefit of 
just over two months in patients with resected PDA receiving gemcita-
bine and capecitabine over gemcitabine alone [3]. The minimal survival 
benefit and known cytotoxicity of these available regimens make it 
imperative to explore novel therapeutic options for these patients. Thus, 
it is important to develop methods that can accurately select patients 
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who may derive benefit from existing targeted therapies (i.e., a 
personalized therapeutic approach). One method to streamline this 
process is to consent a patient for molecular profiling at the time of 
surgical consent, and at the time of resection, send it directly for 
sequencing. Once processed and analyzed these results can be made 
available seamlessly into an electronic health record system for the 
provider [6]. 
The main goal of molecular profiling is to understand the specific 
biologic events driving a patient’s tumor. In the process of profiling, the 
hope is to identify actionable mutations that can be targeted with 
therapy [7]. The foundation of molecular profiling is next generation 
sequencing (NGS) which can identify mutations, gene copy number al-
terations, and rearrangements [8–10], and has been applied in several 
studies of PDA [11–14]. The multitude of potentially actionable muta-
tions identified in PDA parallels other tumor types [7,15–17]. In fact, it 
was estimated in a recent study that roughly a quarter of all PDAs 
sequenced have an actionable mutation [6]. Personalized oncology has 
been applied to recent “basket studies” that categorize patients based on 
their actionable mutation for therapy as opposed to their pathology or 
tumor type [18–22]. 
Based on the aforementioned studies, we aimed to test the feasibility 
of consenting and profiling patients with PDA from a high volume single 
institution practice [23]. We focused primarily on resected PDA pa-
tients, with the ultimate goal to develop a personalized therapeutic 
approach that would complement surgical resection of this disease. 
2. Methods 
2.1. Patients 
For this study, our inclusion criteria included any patient from 
Thomas Jefferson University (TJU) with hepatopancreaticobiliary can-
cers who agreed and gave consent for this study from December 2014 to 
September 2017. All patients had a tissue diagnosis of pancreatic ductal 
adenocarcinoma (PDA) cancer, either endoscopic or surgical, but did not 
have to be a surgical candidate necessarily. For the purposes of this 
study, all other non-PDA samples were excluded for this study analysis. 
Patients were enrolled during December 2014 to September 2017 and 
offered participation in the study. This study was performed with IRB- 
approval and an approved biobanking protocol. 
2.2. Multi-omic profiling and therapy recommendation 
To assess patient tumors for potentially actionable findings, resection 
or biopsy specimens were sent to Perthera, Inc. (McLean, VA) for a 
comprehensive multi-omic profile. Perthera, in collaboration with TJU, 
collected clinicopathologic data, including tumor characteristics and 
past treatment history for correlational analysis. Clinical variables 
included gender, age, smoking history, past medical history (diabetes, 
pancreatitis, hypertension, hyperlipidemia, arthritis, GERD, obesity), 
and family history of cancer. Pathologic variables assessed included 
stage at diagnosis, location of tumor (head vs. body/tail), tumor grade, 
tumor size, pathologic staging, lymph node positivity, presence of IPMN, 
lympho-vascular invasion, and perineural invasion. To see if there were 
any association between pathological variables and molecular variables, 
we performed statistical analysis on NGS samples with a cutoff of three 
or more genes mutated, or IHC samples with a cutoff of four or more 
gene alterations. This yielded 39 variables, for a total of 741 
comparisons. 
Tissue specimens collected were sent to CLIA-certified, CAP- 
accredited labs for two types of profiling: next generation sequencing 
(NGS) using the FoundationOne test from Foundation Medicine, Inc. 
(Cambridge, MA) and protein immunohistochemistry (IHC) from either 
Caris Life Sciences (Irving, TX) or NeoGenomics (Fort Myers, FL). The 
FoundationOne testing platform was used to compare patient sample 
genomics to 315 cancer-related genes plus introns from 28 genes often 
altered in cancer to identify these cancer driver genes [24]. The clinical 
and molecular data were integrated and processed in the Perthera 
Therapeutic Intelligence Engine to generate matching therapies and 
clinical trials. 
2.3. Data infrastructure processing 
To assure a streamline process, samples once collected were sent 
directly to Perthera and their collaborating companies for NGS pro-
cessing and FoundationOne testing. Once the reports were generated, 
Perthera’s molecular tumor board reviewed the treatment recommen-
dations individually and provided a summary to the referring physician. 
The referring physician would then review the findings and conclusions 
with the patients to discuss their therapy options. Further details on the 
Perthera workflow and method development have been previously 
published [6]. 
2.4. Statistical analysis 
Correlations among molecular and clinicopathologic variables were 
assessed using Fisher’s exact test, implemented with the fisher.test 
function in the stats package of the R statistical programming language. 
Correlations between molecular and clinicopathologic variables and 
recurrence-free survival (RFS) and overall survival (OS) were assessed 
using a log-rank test of Kaplan-Meier survival estimates, implemented 
using the survdiff function in the survival package of R. 
3. Results 
3.1. All samples: tissue collection rates for all patients included 
During the study timeframe, Perthera delivered multi-omic profiling 
reports for a total of 78 TJU patients with hepatopancreaticobiliary 
cancers. The majority of these were pancreatic ductal adenocarcinoma 
cases (PDA, n ¼ 65, Table 1), and the remaining 13 cases were non-PDA 
cancers and were excluded from this study analysis. Although tissue 
specimen quality is often a limiting factor in obtaining molecular test 
results, genomic and proteomic profiling had high success rates in this 
study. NGS results were obtained for all the patients, while IHC results 
were obtained for nearly all the patients (75/78, 96%). For the current 
analysis, we focused only on PDA samples collected for molecular 
testing (n ¼ 65) for this study’s analysis. 
3.2. Multi-omic profiles reveal therapeutic actionability in half of the 
patients with PDA 
Actionable alterations are defined as mutations in the person’s 
genome that can be specifically targeted by molecular therapies against 
Table 1 
Type of tumor and resection in this cohort of patients: Summary of all 65 patients 
included in the study with baseline demographics, diagnosis and status at tissue 
collection.   
Surgery Biopsy 
Diagnosis   
Pancreatic Adenocarcinoma 52 13 
Age   
<50 2  
50–59 11 1 
60–69 20 7 
>70 19 5 
Gender   
Male 25 8 
Female 27 5 
Status at Tissue Collection   
Localized/Borderline Resectable 51 1 
Metastatic 0 13  
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that mutation. In the 65 PDA cases, pathogenic mutations were detected 
in all tumor specimens, with a median of 3.5 pathogenic mutations or 
copy number alterations (CNA) per patient. Common PDA driver mu-
tations were present at the expected frequencies (Fig. 1) [12]: KRAS 
mutations [25] were seen in 62/65 (95%) cases, TP53 mutations [25] 
found in 49/65 (75%), CDKN2A mutations or losses [25] found in 25/65 
(38%), and SMAD4 mutations or losses [25] found in 16/65 (25%). 
Additionally, out of the 65 patients with PDA, 47% of patients had 
mutations in targetable genes, such as genes important for homologous 
recombination [26] (11/16, 17%), or AKT/PIK3CA amplification [27] 
and ARID1A/STK11 mutations [27] involving the PI3K/mTOR pathway 
(8/65, 12%)—these are actionable mutations that can be targeted with 
therapies that exploit these mutations and pathways. 
As published in large sequencing studies [28,29], the most common 
actionable alterations in PDA patients were mutations in the DNA 
damage response pathway 8–10% [6,30,31] which can be targeted by 
platinum agents and PARP (poly ADP ribose polymerase) inhibitors. 
Other less common actionable abnormalities (and the potential associ-
ated therapies) included FGFR alterations (FGFR inhibitors; 5/65, 8%); 
HER2 amplifications [32] and/or ERRB2 activating mutations (HER2 
inhibitors, 3/65, 5%), and RNF43/GNAS/FAT1 mutations important for 
the WNT pathway [33,34] that can be targeted with WNT inhibitors 
(3/65, 5%, Fig. 1). 
3.3. Correlations among molecular and clinical variables 
Molecular and clinicopathologic data were systematically analyzed 
for correlations in the 52/65 surgically resected PDA specimens. Clinical 
variables included gender, age, smoking history, other medical condi-
tions and family history of cancer. Testing for associations using Fisher’s 
exact test revealed that 36 of these comparisons were significant at a 
threshold of p < 0.05 (Table 2). 
Multiple significant correlations (p < 0.05) between common PDA 
driver genes were observed. CDKN2A mutations or copy number losses 
were more frequent when TP53 was mutated (p ¼ 0.031). SMAD4 mu-
tations were more common in tumors with mutations at the p14 ARF 
locus of CDKN2A (p ¼ 0.011). Several correlations were found between 
the four common PDA drivers (TP53, SMAD4, CDKN2A, PTEN) and 
certain pathological and molecular features. For example, all tumors 
with PTEN protein loss had CDKN2A mutations/loss (p ¼ 0.0027), and 
high protein expression of PD-1 was more frequently observed in pa-
tients with loss of CDKN2B (p ¼ 0.048), as seen in Table 2 (for diagnosis, 
complete NGS sequencing, and proteomic results for each patient see 
Table 3). 
3.4. Patient outcomes and therapy selection 
Of the 65 patients with PDA, 52 patients underwent surgical resec-
tion and outcomes data were collected on patients who continued 
receiving care at TJU. Median overall follow-up time was 459 days from 
time of initial diagnosis. Of the surgically resected patients with avail-
able outcomes, 14/42 (33.3%) had no evidence of disease or had 
recently developed disease recurrence as of last follow-up (Fig. 2). 
Eleven of these patients were on standard of care adjuvant chemo-
therapy, with initial therapies listed in Fig. 2. One of these followed a 
molecularly matched therapy recommendation: a patient with a BRCA2 
mutation enrolled in a trial of a PARP inhibitor in combination with 
FOLFOX (folinic acid, 5- fluorouracil, oxaliplatin). 
3.5. Survival analysis 
Of the 52 patients with resected PDA, we screened the 39 molecular 
and clinicopathologic features (see Methods for details) against survival 
data to evaluate correlations with recurrence-free and overall survival. 
Median follow-up time was 459 days from initial diagnosis. Further 
analysis of the data showed that almost half of the patients (23/52) had 
developed disease recurrence, with a Kaplan-Meier estimate of median 
RFS of 12.4 months. In the patients who did develop disease recurrence, 
Fig. 1. Driver and actionable mutations: Summary of all mutations identified using NGS in the 65 patients with PDA. From those 65 patients, actionable mutations 
with specific therapeutic options are identified in blue, with common PDA driver genes identified in yellow. 
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most recurrences were in the liver (17 patients), lung (1 patient), brain 
(1 patient), bone (1 patient), omentum (1 patient), lymph node (1 pa-
tient), and one patient had a locally recurrent tumor. Molecular profiling 
was not repeated after recurrence had occurred in these patients. Fewer 
than half of the patients (20/52) were deceased, with a Kaplan-Meier 
estimate of median OS of 21.7 months. 
Five variables were correlated with RFS. High expression of three 
proteins, ERCC1 (p ¼ 0.001), TS (p ¼ 0.005), and PD-1 (p ¼ 0.04), were 
associated with lower RFS (Fig. 3). Interestingly, TP53 mutations were 
correlated with longer RFS (p ¼ 0.01). High tumor grade was negatively 
correlated with RFS (p ¼ 0.04). No molecular variables were correlated 
with OS, but two pathologic features were associated with shorter OS: 
tumor size over 3 cm (p ¼ 0.002) and high histologic grade (p ¼ 0.02). 
4. Discussion 
There is a pressing need in today’s health care setting for a facile 
system wherein patient consenting is seamlessly tied to molecular ana-
lytic workflow and tracked throughout the course of a patient’s treat-
ment. Integrated, structured data are critical for applying statistical and 
artificial intelligence-based or heuristic algorithms that will be neces-
sary to detect complex relationships between patient data, treatment 
data, molecular data and treatment response. In this study, we sought to 
take a first-step to address these data infrastructure-related challenges 
and demonstrate that a comprehensive precision medicine program can 
Table 2 
Correlations among molecular and clinicopathologic features: For the patients 
with PDA, mutated NGS markers (>3) are listed in red text, while altered IHC 
markers (>4) are listed in orange text. Using Fisher’s exact test association 
testing was performed to identify significant variables that correlated between 
the clinical and molecular variables in patients with PDA. These significant 
variables are shown on the table. LVI: lympho-vascular invasion, GERD: 
gastroesophageal reflux disease.  
Variable 1 Variable 2 p value Odds ratio 
LVI present Positive lymph node, N1 6.50E-07 73.9 
Hyperlipidemia Hypertension 3.60E-04 10.9 
IHC: ERCC1 IHC: TS 5.90E-04 14.4 
NGS: CDKN2A NGS: CDKN2B 9.10E-04 Infinity 
GERD Hyperlipidemia 0.0023 8.1 
IHC: PTEN NGS: CDKN2A 0.0027 0 
Hypertension NGS: DNMT3A 0.0033 Infinity 
NGS: CDKN2A NGS: CDKN2ARF 0.0033 Infinity 
GERD Hypertension 0.0035 6.9 
Metastatic presentation NGS: BRCA2 0.0067 64 
Gender, male IHC: TS 0.0097 0.2 
NGS: CDKN2ARF NGS: SMAD4 0.011 15.7 
Hypertension Obesity 0.011 Infinity 
Family cancer history Size, > 3 cm 0.014 0.2 
NGS_DNMT3A Size, > 3 cm 0.018 Infinity 
Grade 3/4 IHC: MET 0.019 0 
Age >66 Recent smoker 0.019 0.2 
Age >66 NGS: CDKN2ARF 0.02 Infinity 
NGS: BRCA2 Location, pancreatic head 0.021 0 
IHC: TS Obesity 0.024 Infinity 
Location, pancreatic head Pancreatitis 0.027 6 
Family cancer history IHC: ERCC1 0.028 8 
Diabetes Hypertension 0.028 4.2 
NGS: CDKN2A NGS: TP53 0.031 5.4 
Diabetes IHC: PTEN 0.031 0.1 
Arthritis Obesity 0.034 12.1 
Hyperlipidemia NGS: DNMT3A 0.034 9.9 
Family cancer history Metastatic presentation 0.036 18.4 
Age >66 IHC: PD1 0.039 0.1 
Arthritis Hyperlipidemia 0.042 4.1 
NGS: TP53 Location, pancreatic head 0.044 4 
Grade 3/4 NGS: DNT3A 0.047 8.7 
IHC: PD1 NGS: CDKN2B 0.048 11.2 
Age >66 IHC: PTEN 0.048 Infinity 
IHC: TUBB3 NGS: ARID1A 0.049 0 
Grade 3/4 LVI present 0.05 5.2  
Table 3 
A summary of each patient’s sex, pathologic diagnosis, all relevant sequence 
coding region sequence changes, and proteomic findings.  
SEX DIAGNOSIS GENOMIC FINDINGS 
Male Pancreatic adenocarcinoma HER2 S310F, KRAS G12D, p53 
R282W, CSF1R T37M, GATA6 
Amplification, RBM10 Y508* 
Male Pancreatic adenocarcinoma HER2 Amplification, KRAS 
G12R, p53 H193P, MYC 
Amplification 
Male Pancreatic adenocarcinoma CHEK2 T367fs*15, KRAS 
G12D, NF1 Truncation exon 
35, DNMT3A C818* 
Female Pancreatic adenocarcinoma KRAS G12V, p53 R248W, 
CDKN2A Loss, SMAD4 
V112fs*8 
Female Pancreatic adenocarcinoma KRAS G12D, p53 Y220C, 
CDKN2A R80*, SMAD4 R361C 
Female Pancreatic adenocarcinoma BRCA2 T3085fs*19 
Male Pancreatic adenocarcinoma KRAS G12V, p53 P153fs*28, 






R499W, TERC Amplification 
Male Pancreatic adenocarcinoma KRAS G12D, p53 I195F, 






Amplification, LRP1B deletion 
exon 4-16 
Male Pancreatic adenocarcinoma ATM K2589fs*8, KRAS Q61R, 
p53 L43fs*9, CDKN2A Loss, 
SMAD4 V163fs*3, GATA6 
Amplification, MAGI2 M593V, 
SLIT2 A276T 
Male Pancreatic adenocarcinoma KRAS G12D, p53 Y163C, 
PRKN Rearrangement 
Male Pancreatic adenocarcinoma BRCA2 C1200fs*1, HER2 
H878Y, KRAS G12R, SMAD4 
D493H, SMAD4 V335fs*48, 
BRCA2 R2336H 
Male Pancreatic adenocarcinoma KRAS G12D, p53 
K319_K320insKKPLDGEYFT*, 
AKT2 Amplification, CCNE1 
Amplification 
Male Pancreatic adenocarcinoma KRAS G12D, p53 
M237_N239del2 
Male Pancreatic adenocarcinoma KRAS G12D, p53 C176Y, 
CDKN2A R80*, CDKN2A 
Truncation, intron 1, AKT2 
Amplification, MYC 
Amplification 
Male Pancreatic adenocarcinoma KRAS G12V, p53 A159fs*21, 
ARID1A Q575*, ARID1A 
S1828*, SLIT2 N775S 
Female Pancreatic adenocarcinoma FGFR1 Amplification, KRAS 
G12V, p53 H214R, CDKN2A 
Loss 
Male Pancreatic adenocarcinoma KRAS G12V, p53 G266E 
Male Pancreatic adenocarcinoma KRAS G12D, p53 P278L, 
CDKN2A R22_G23del 
Female Pancreatic adenocarcinoma KRAS G12V 
Female Pancreatic adenocarcinoma PALB2 P1152fs*9, FGFR2 
P253R, PALB2 S804fs*10, 
PRKCI Amplification, SLIT2 
A276T, TERC Amplification 
Male Pancreatic adenocarcinoma KRAS Q61H, ARID1A 
R1335*2 
Female Pancreatic adenocarcinoma ATM K1066fs*6, KRAS G12D, 
MDM2 Amplification, ARID1A 
Y216*, FRS2 Amplification, 
(continued on next page) 
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Table 3 (continued ) 
SEX DIAGNOSIS GENOMIC FINDINGS 
ATM W1710*, KMT2D 
P601fs*329 
Female Pancreatic adenocarcinoma KRAS G12D, p53 G266E 
Male Pancreatic adenocarcinoma KRAS G12D, p53 M133K, 
CDKN2A H83D, SMAD4 Loss, 
MUTYH Y165C 
Female Pancreatic adenocarcinoma BRCA1 Rearrangement intron 
2, KRAS G12V, p53 R249S, 





Male Pancreatic adenocarcinoma KRAS G12D 
Female Pancreatic adenocarcinoma KRAS G12D, p53 C124*, 
CDKN2A Loss 
Female Pancreatic adenocarcinoma KRAS G12V, p53 R213*, 
CDKN2A Loss, RICTOR 
Amplification, STAG2 
X435_splice 
Male Pancreatic adenocarcinoma KRAS G12D, p53 R175H, 
GNAS R201H, RNF43 E43* 
Female Pancreatic adenocarcinoma KRAS G12D, p53 C176F, 
CDKN2A Loss, RNF43 
E777fs*10þ, GATA6 
Amplification 
Female Pancreatic adenocarcinoma BARD1 S551*, KRAS G12R, 
p53 Q136*, p53 S366A, 
CDK12 Truncation, CDK12 
Truncation exon 10, MYC 
Amplification, DNMT3A 
R729W, GRM3 D280N, MYC 
Amplification equivocal, 
RUNX1T1 R520H 
Male Pancreatic adenocarcinoma ABL2 Rearrangement, KRAS 
Q61H 
Female Pancreatic adenocarcinoma KRAS G12R, p53 W91*, 
SMAD4 R445* 
Female Pancreatic adenocarcinoma KRAS G12V, p53 V157F, 
CDKN2A Loss 
Female Pancreatic adenocarcinoma KRAS G12V, p53 A76fs*55, 
SMARCA4 T910M 
Female Pancreatic adenocarcinoma BRCA2 L557*, KRAS G12V, 
p53 R248W, CDKN2A 
X51_splice, CDKN2A 
X0_splice, DNMT3A R882H, 
FAT1 Y4540fs*8, HGF 
Amplification, EPHB1 R79W, 
HGF Amplification equivocal 
Male Pancreatic adenocarcinoma KRAS Q61H, p53 R213*, 
CDKN2A A17fs*9 
Female Pancreatic adenocarcinoma KRAS G12V, p53 R248Q 
Male Pancreatic adenocarcinoma KRAS G12D, CDKN2A H83R 
Female Pancreatic adenocarcinoma KRAS G12V, p53 G334V, 
BRSK1 Loss exon 2-17 
Male Pancreatic adenocarcinoma KRAS Q61H, p53 Q192*, 
CDKN2A R87fs*21, SMAD4 
W302*, KDM6A E226*, 
PBRM1 R710*, HGF E199K, 
LRP1B D2702N 
Female Pancreatic adenocarcinoma KRAS G12R, p53 X307_splice, 
SMAD4 R361H, SMAD4 
R445*, CCND3 Amplification, 
VEGFA Amplification, APC 
I2615fs*1, TMB Intermediate 
Male Pancreatic adenocarcinoma KRAS G12V, p53 V157F, 
NOTCH2 Amplification 
Male Pancreatic adenocarcinoma KRAS Q61R, p53 R337C, 




Female Pancreatic adenocarcinoma KRAS G12D, p53 R213W, 
CDKN2A H83Y, SMAD4 
C523*, ARID1A D322fs*40, 
TMB Intermediate  
Table 3 (continued ) 
SEX DIAGNOSIS GENOMIC FINDINGS 
Male Pancreatic adenocarcinoma KRAS G12R, p53 Y220C, 
CDKN2A Loss, TGFBR2 R537C 
Male Pancreatic adenocarcinoma KRAS G12D, p53 R282W, 
CDKN2A Loss, SMAD4 
Truncation intron 4, SMAD4 
Truncation, NOTCH3 deletion 
exon 7–31, NOTCH3 deletion 
Female Pancreatic adenocarcinoma KRAS G12V, p53 D49fs*76, 
RBM10 L195fs*71 
Female Pancreatic adenocarcinoma KRAS G12D 
Female Pancreatic adenocarcinoma KRAS G12D, p53 R175H, 
NTRK3 K732T 
Male Pancreatic adenocarcinoma KRAS G12V, p53 R196*, 
CDKN2A L94P 
Female Pancreatic adenocarcinoma KRAS G12D, p53 R282W 
Female Pancreatic adenocarcinoma KRAS G12D, SMAD4 S474* 
Male Pancreatic adenocarcinoma p53 R282W 
Male Pancreatic adenocarcinoma KRAS G12C, p53 G245D, 
MYCL R330*, VEGFA 
Amplification, SF3B1 K666R, 
VEGFA Amplification 
equivocal 
Male Pancreatic adenocarcinoma KRAS G12D, p53 V218E, 
CDKN2A A100fs*46, NF1 
X244_splice 
Female Pancreatic adenocarcinoma KRAS G12D, p53 D281fs*31, 
KDM6A A516fs*9, SETD2 
X2037_splice, DNMT3A 
K844*, TMB Intermediate, 
SPTA1 T681fs*76 
Male Pancreatic adenocarcinoma KRAS G12D, p53 C141fs*8 
Female Pancreatic adenocarcinoma KRAS G12D, p53 P322fs*23, 
ARID2 Loss, ARID2 Loss exon 
17-21 
Male Pancreatic adenocarcinoma FANCG W599fs*49, KRAS 
G12V 
Female Pancreatic adenocarcinoma KRAS G12D, DNMT3A R771* 
Female Pancreatic adenocarcinoma KRAS G12V, p53 H193R, 
SMAD4 W99*, CUL3 R709Q 
Female Pancreatic adenocarcinoma KRAS G12V, p53 V173L, 
CDKN2A deletion exon 2, 
CDKN2A deletion exon 2 - 
intron 2, SMAD4 Q116*, FRS2 
Amplification 
Female Pancreatic adenocarcinoma ATM Q1084fs*9, KRAS G12V, 
CDKN2A M54del, SMAD4 
Q28* 
Male Pancreatic adenocarcinoma KRAS G12V, SMAD4 
Truncation intron 8 
Female Pancreas neuroendocrine 
carcinoma 
MEN1 L89R 
Female Extrahepatic cholangiocarcinoma STK11 R304W, MDM2 
Amplification, FRS2 
Amplification, U2AF1 S34F 




Male Extrahepatic cholangiocarcinoma KRAS Amplification, KRAS 
G12V, p53 G293fs*13, SF3B1 
K700E 
Female Extrahepatic cholangiocarcinoma SPEN M2790V, KRAS G12V, 
CTNNB1 S45F, CD36 C243* 
Male Duodenal adenocarcinoma KRAS G12D, p53 R213*, 
ERBB3 G284R 
Male Colon adenocarcinoma KRAS G12V, GNAS R201H 
Male Ampullary adenocarcinoma KRAS G12D, APC K1543fs*2, 
FH V435M, MAP2K4 S251N 
Male Ampullary adenocarcinoma BARD1 Y404fs*1, CIC 
G797fs*114 
Male Ampullary adenocarcinoma BRCA2 E1518fs*25 
Female Ampullary adenocarcinoma HER2 D769Y, p53 G245V 
Female Solid pseudopapillary neoplasm of the 
pancreas 
CTNNB1 S37A 
Female Solid pseudopapillary neoplasm of the 
pancreas 
CTNNB1 I35_G38del 
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be integrated into cancer care as part of a large clinical practice focused 
on pancreatic cancer. 
Recent studies have demonstrated that precision medicine can sug-
gest alternative therapeutic strategies in roughly 50% of pancreatic 
cancer patients [6,35,36]. Of the 52 surgically resected PDA patients in 
this study, 48% harbored at least one actionable alteration, similar to 
some other studies published [6,30,36]. While DNA repair genes and 
PI3K/mTOR pathway genes had actionable mutations in a relatively 
high number of patients, no single therapeutic target dominated the 
actionable alterations (Fig. 1). This suggests that profiling of a broad 
panel of genes is important in PDA in order to identify all potential 
targets. We note that the frequencies of actionable alterations, in 
addition to the four common PDA driver alterations, did not differ 
greatly from published datasets [28,37–39] or from the Know Your 
Tumor dataset of over 600 patients [6]. 
One major limitation of this study, and indeed of all similar profiling 
studies that have been published [30], is that a limited number of pa-
tients that had actionable molecular alterations have gone on to receive 
matched targeted therapies, especially in a clinical trial. Therefore, it is 
impossible to draw conclusions about the overall clinical effectiveness of 
this approach. Moreover, overall follow-up, to date, is not yet long 
enough to draw any meaningful conclusions about overall impact of the 
platform on patient care (to this point, in this study 76% of the surgically 
resected patients have not yet received treatment for recurrent or met-
astatic disease). 
Although we could not perform a statistical analysis correlating 
molecular and clinicopathologic features with treatment data, we were 
TMB was either low or not reported unless otherwise specified; Microsatellite 
instability was not detected in any of these cases. 
Fig. 2. Outcomes collection: Summary of overall outcome data available from patients with PDA enrolled in the study. Outcome data for patients who had long 
term follow-up in TJU system is represented as of 2018 when the charts were last reviewed with details on any treatment ongoing. NED: no evidence of disease, 5-FU: 
5-fluorouracil. 
Fig. 3. Recurrence-free survival (RFS) is 
correlated with molecular and pathologic 
features: From the patients with PDA who 
had long term follow-up at TJU, Kaplan 
Meier graphs were generated to assess RFS. 
High expression of ERCC1 (A), TS (B), and 
PD-1 (C) were correlated with lower RFS. 
Additionally, mutations in TP53 were corre-
lated with higher RFS(D), while high grade 
tumors had lower RFS (E). All graphs shown 
are statistically significant with p values 
indicated on the graphs.   
C.Y. Lowder et al.                                                                                                                                                                                                                              
Surgical Oncology 33 (2020) 118–125
124
able to find correlations with the time interval of recurrence-free sur-
vival (RFS). The high number of significant correlations with RFS 
(Fig. 3) in this relatively small dataset suggests that as the number of 
patients analyzed using this platform grows, treatment-specific corre-
lations should become readily detectable. Of the five biomarkers that 
were significantly correlated with RFS, three were protein-based: 
ERCC1, TS and PD-1. These markers are putative predictive markers 
for chemotherapeutic (5-FU) efficacy [40], platinum based therapy 
resistance [41], and potentially future immunotherapeutic strategies. 
This work supports the notion that proteomic-based testing may also 
provide additional information for survival and response rates. Inter-
estingly, in our current patient subset we also found that there was an 
increase in RFS in patients with TP53 mutations compared to TP53 
wildtype, which contradicts what was previously published [42]. There 
have been some inconsistencies in the literature over TP53 mutations 
and prognostic significance, with some articles considering it a negative 
prognostic indicator [43] and some articles showing no significance [44, 
45]. 
Our study establishes that profiling surgically resected primary 
pancreatic tumors yields a comparable amount of actionable alterations 
to profiling studies of metastatic sites. This is consistent with studies that 
showed actionable NGS alteration frequencies did not differ between 
primary and metastatic PDA [46,47]. Performing molecular profiling on 
surgical tissue specimens has multiple important benefits for the time-
line of patient care. First, it allows for enough time to plan for therapy if 
recurrence occurs. This may facilitate enrollment in molecularly tar-
geted clinical trials in the first line of therapy setting, when there is a 
greater chance of deriving benefit. For example, one patient in a sepa-
rate study that had a rare IDH1 mutation received an IDH1 inhibitor as 
third line therapy after developing resistance to FOLFIRINOX (folinic 
acid, 5- fluorouracil, irinotecan, oxaliplatin) and gemcitabine with 
nab-paclitaxel [48]. This patient did not respond to the IDH1 inhibitor, 
but it is possible that earlier molecular profiling of her tumor could have 
led to earlier initiation of targeted therapy and a better response [48, 
49]. Second, profiling surgical specimens allows time to study the tu-
mor’s biology and propagate ex vivo models for various drug sensitivity 
assays (e.g., organoid model) [29,50]. Third, profiling a tumor after the 
administration of neoadjuvant therapy, would allow for a more accurate 
assessment of the tumor after it has been exposed to potent DNA 
damaging agents. Finally, this work lays the groundwork for the po-
tential of a personalized adjuvant therapy for patients with lymph node 
positivity and R1/R2 resections. Based on these theories highlighting the 
utility of molecular profiling in an oncological setting, there are a couple 
of potential points of therapeutic intervention (Fig. 4). With the use of 
NGS and molecular profiling we can use this additional information to 
guide oncological therapy in the neoadjuvant and adjuvant settings to 
allow for the administration of a more unique and personalized therapy 
for the patient. 
In the future, molecular profiling combined with focused drug 
screens in ex vivo cultures, may inform a personalized approach to 
treating pancreatic and other cancers. Future randomized controlled 
trials, along with the optimization of targeted approaches, will deter-
mine whether and when molecular profiling will have a role in the 
treatment of patients with resectable disease (Fig. 4). This type of pre-
cision medicine platform may allow large hospital systems, such as ours, 
and cooperative groups to facilitate next generation molecular tumor 
boards in an effort to scale precision medicine for the benefit of large 
numbers of patients. 
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